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controlled trials of BTX-A for chronicmigraines. Differences were
settled via consensus. Data extraction/veriﬁcation were managed
similarly. The primary outcome was baseline-endpoint change in
migraine frequency (number/month). Heterogeneity was assessed
using c2 and I-squared. Two raters assessed study quality using the
Downs-Black scale, with adjudication via consensus. A ﬁxed-
effects model combined study results using the standardized mean
difference (Cohen’s d) in monthly migraine frequency between
placebo and BTX-A groups. RESULTS: Nine trials (N = 2114;
BTX-A = 1388, placebo = 726; 2059 completed their trials) pro-
vided data in 19 study arms and 9 placebo arms. The average age
was 43 +/- 3, duration of illness was 20 +/- 3 years, average
number of migraines was 6.0 +/- 2.1/month, 84% were females.
All c2 were non-signiﬁcant; all I-suared were 0, suggesting com-
binability and conﬁrmed using a ﬁxed-effects model. Quality
scores averaged 67% +/- 4% (“fair”; range:62%–75%). The
weighted average treatment effect (Cohen’s d) of BTX-A over
placebo was -0.05 (CI95% = -0.13, 0.03) when measured 30
days after injection, -0.04 (CI95% = -0.12, 0.04) at 60 days, and
-0.04 (CI95% = -0.12, 0.04) at 90 days post-injection. Two
comparisons out of 57 were signiﬁcant; one by Relja after 60 days
and one by Vo after 90 days. Controlling for placebo effect and
stratifying by dose stratiﬁcation found no signiﬁcant effect of
BTX-A in reducting migraine frequency per month over saline
vehicle. CONCLUSION: BTX-A used as prophylactic treatment
of chronic migraine headaches does not decrease monthly
numbers of migraines.
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OBJECTIVE: To simultaneously assess risk of acute myocardial
infarction (AMI), any cardiovascular (CV) and gastrointestinal
(GI) events with traditional non-selective NSAIDs (tNSAIDs)
and COX-2-inhibitors (coxibs). METHODS: Using the
PHARMO Record Linkage System, including drug-dispensing
and hospitalization data of >2 million residents of The Neth-
erlands, subjects with a ﬁrst hospitalization for AMI, any CV,
and GI diagnoses were identiﬁed. NSAID and coxib use was
classiﬁed into remote, recent and current use. Naproxen users
were excluded. Cases were matched to controls in a 1 to 4 ratio
on age and date. Multivariate analyses adjusted for gender,
history of hospitalizations and medications. RESULTS: Com-
pared with remote use, AMI risk was increased among current
users of coxibs combined (adjusted OR 1.63, 95% conﬁdence
interval 1.24–2.16) and among current users of tNSAIDs com-
bined (adjusted OR 1.29, 95% CI 1.08–1.55). AMI risk with
current use of celecoxib (1.63, 1.09 3.54), rofecoxib (1.59,
1.15–2.19), ibuprofen (1.54, 1.13–2.09) and diclofenac (1.43,
1.13–1.82) was signiﬁcantly increased. Risk of any CV event
with current use of celecoxib, rofecoxib, diclofenac and
tNSAIDs other than ibuprofen or diclofenac was signiﬁcantly
increased (adjusted OR ranged from 1.22 to 1.70) . GI risk
with current use of rofecoxib (1.73, 1.27–2.35), ibuprofen
(1.40, 1.00–1.95), diclofenac (4.40, 3.55–5.44) and other
tNSAIDs (2.38, 1.86–3.04), but not celecoxib (1.06, 0.47–2.35)
was signiﬁcantly increased. Compared with current use of
celecoxib, adjusted AMI and CV risk was not signiﬁcantly
increased with current use of individual coxibs and individual
tNSAIDs ,but GI risk was increased with diclofenac (adjusted
OR 4.17, 95% C.I. 1.83–9.51). CONCLUSION: AMI and CV
risk was similarly increased with individual coxibs and
tNSAIDs. Use of diclofenac strongly increased GI risk. Residual
confounding and “channelling” can not be excluded.
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OBJECTIVE: To provide cross-cultural comparisons of health
and behavior in obese individuals. METHODS: We analyzed
data from the 2006 National Health and Wellness Survey, a
cross-sectional Internet-based survey conducted annually in the
United States and EU (FR, DE, UK, SP and IT). When
weighted, the sample is representative of the country’s adult
population in terms of key sociodemographic characteristics.
The survey gathers information regarding demographics, health
conditions, quality of life, and health care use. Adults were
classiﬁed as overweight/obese (OWOB) based on BMI >= 25.
Comparisons between groups were conducted using the Chi-
square test with a signiﬁcance level of p < 0.05. RESULTS:
Almost 70% (144 M) of the United States population is
OWOB, compared to just over half of Europeans (131 M). In
both regions the OWOB populations were typically married
and employed, with a mean age of 48 yrs (USA) and 51 yrs
(EU) (p < 0.05). Both had high rates of cardiovascular
co-morbidities and a family history of obesity or diabetes. The
majority reported having less than very good health and “some/
little/no” energy in the past four weeks. Most had seen a health
care provider in the past six months (82% USA vs. 87% EU;
p < 0.05). Although many claimed to be taking steps to lose
weight (62% US vs. 50% EU; p < 0.05), most reported weight
gain over the past 6 months (30% US vs. 28% EU, p < 0.05).
Only a small portion reported taking a weight-loss prescription
(1.9% US vs. 3.5% EU, p < 0.05); but most of the remainder
would consider taking one (45% US vs. 36% EU, p < 0.05).
CONCLUSION: The obesity problem is more evident in the
United States. Americans exhibit higher rates of obesity at a
younger age but have fewer provider visits and use of prescrip-
tions, suggesting potential solutions to the problem.
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OBJECTIVE: Pain symptoms are common among adults aged
65 and older, but prevalence rates have not been updated to
reﬂect current national data. We assess prevalence among U.S.
adults aged 65 and older with respect to pain (joint, lower
back, neck, severe headaches or migraines) and describe symp-
toms by gender, obesity, and arthritis status. METHODS:
Analysis of nationally representative data collected from adults
aged 65 and older (n = 3810) participating in the National
Health and Nutrition Examination Survey (NHANES) 1999–
2004. RESULTS: Joint pain and lower back pain are the most
frequently reported type of pain, affecting 55% and 38% of
elders, respectively. Women are signiﬁcantly more likely than men
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